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a  b  s  t  r  a  c  t
Astaxanthin  is believed  to  be beneﬁcial  to  human  health  because  it possesses  strong  antiox-
idant properties.  A  natural  astaxanthin-rich  carotenoid  extract (ARE)  was  produced  by
a well-controlled  fermentation  of  a natural  bacteria  Paracoccus  carotinifaciens,  followed
by the  extraction  and  enrichment  of the  ﬁnal  product  comprising  mixture  of  carotenoids
that  is  predominantly  astaxanthin.  The  aim  of this  study  was  to  evaluate  the  sub-chronic
toxicity  of  the  ARE  using  6 week  old  Sprague-Dawley  SPF  rats  [Crl:CD(SD)].  The  test  arti-
cle was  suspended  in olive  oil  and administered  daily  to  the  rats  by oral  gavage  for  13
weeks  at  doses  of  0 (olive  oil),  250,  500  or 1000  mg/kg/day.  Each  group  consisted  of 10
animals  of  each  sex.  No  deaths  occurred  and  no  treatment-related  changes  were  observed
in the  detailed  clinical  observations,  manipulative  tests,  grip  strength,  motor  activity, body
weights,  food  consumption,  ophthalmology,  urinalysis,  hematology,  blood  chemistry,  organ
weight, necropsy  or histopathology.  Dark-red  feces  were  observed  throughout  the  admin-
istration period  in  all treated  groups  due  to  excretion  of  the  colored  test  article.  Based  on
these results,  it  was  concluded  that  the  no  observed  adverse  effect  level  (NOAEL)  for ARE
was  at  least  1000  mg/kg/day  for male  and  female  rats, respectively.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
the CC BY license  (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Astaxanthin is an oxycarotenoid (i.e., possesses oxy-
gen  functional groups), and part of the xanthophyll group
of  carotenoids believed to provide health beneﬁts by
decreasing the risk of disease in humans [1–5]. Astaxanthin
is  also one of the dominant carotenoid contributors to the
orange/red coloration found in salmon, shrimp and krill.
The  same coloration can be transferred to animals that eat
∗ Corresponding author. Tel.: +1 410 960 1062.
E-mail address: DHA4ME@gmail.com (D. Kyle).
http://dx.doi.org/10.1016/j.toxrep.2014.08.008
2214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. 
(http://creativecommons.org/licenses/by/3.0/).large amounts of these astaxanthin-rich food sources (e.g.,
ﬂamingoes). The ultimate producers of oxycarotenoids
however are photosynthetic or microbial species that can
be  found in the aquatic environment (e.g., algae) or as ter-
restrial  plants and microorganisms. Although we  recognize
the  presence of astaxanthin by its red or orange color, its
cellular  biochemical role is thought to be based on the pow-
erful  antioxidant characteristics of this molecule [6–9].
Astaxanthin can exist as several stereoisomers since the
molecule has two  chiral centers at carbons 3 and 3′ (Fig. 1).
Both  chiral centers can exist in either the R or S form and
there  are four possible stereo (or optical) isomers: SS, RS,
SR,  or RR. Astaxanthin can also be present in cells in a free
This is an open access article under the CC BY license
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mFig. 1. Chemical structure of astaxanthin showi
orm or esteriﬁed to certain fatty acids [10]. Astaxanthin
roduced by the algae Heamatococcus pluvialis is esteriﬁed
nd  in the 3S, 3′S form, whereas that produced by the yeast
hafﬁa  rhodozyma is nonesteriﬁed and in the 3R, 3R’ form,
nd  that produced by the bacteria Paracoccus carotinifa-
iens is also nonesteriﬁed but in the 3S, 3′S form. Synthetic
staxanthin is used extensively worldwide as a coloring
gent in salmon aquaculture and it is a racemic mixture of
ll  optical isomers and in the non-esteriﬁed form. In wild
tlantic  or Coho salmon the dominant form of astaxanthin
s  nonesteriﬁed and in the 3S, 3′S form similar to that of
.  carotinifaciens. These nuances in the chemical structure
f  astaxanthin can, and has been used as a ﬁngerprint to
stablish  the source of pigmentation (synthetic or natural)
n  farm raised ﬁsh [11].
P.  carotinifaciens is a gram-negative, aerobic, rod-shaped
acterium with a high content of natural carotenoid. It
s  a member of the alpha-3 subclass of the Proteobacteria
nd classiﬁed in the genus Paracoccus based on the organ-
sm’s  genotypic and phenotypic characteristics and DNA
omposition [12]. Both the alga H. pluvialis (commercially
old as NaturRose®) and yeast P. rhodozyma (commercially
®old as Ecotone ) contain astaxanthin as the vast majority
f  the total carotenoid in the cells (92% and 73% respec-
ively), but the relatively low total carotenoid content of
he  cells (1.75% and 0.62% by weight respectively) results
ig. 2. Proposed biosynthetic pathways from B-carotene to astaxanthin in Paraco
inor  ﬂux pathway (dashed line) and demonstrating the intermediate carotenoidwo  chiral centers (3, 3′) in the 3R and 3′S form.
in  a relatively low absolute Astaxanthin level on a gram
dry  weight basis (i.e., 1.6% and 0.45% respectively). The
carotenoids present in P. carotinifaciens (commercially sold
as  Panaferd®) on the other hand, represent a range of nat-
ural  carotenoids in the biosynthetic pathway leading to
astaxanthin (Fig. 2), some of which are known to have a
considerably higher antioxidant potential than astaxan-
thin  itself [13]. Although the astaxanthin only represents
55–60% of the total carotenoid of the cells, the high total
carotenoid level (4.1% by weight) results in a ﬁnal astaxan-
thin  level of 2.2% of the biomass.
Several  toxicology studies including in vitro and in vivo
mutagenicity studies, as well as repeat-dose toxicity stud-
ies  in rats, using intact P. carotinifaciens dry cells have been
performed to assess the safety of the whole cell biomass
as  a potential natural pigment source for the coloration of
farm  raised salmon and trout [14]. No notable toxicities for
this  organism have been observed and, as a result, the dry
cell  biomass has been approved for use as a natural color-
ing  agent in salmon and trout aquaculture by the United
States Food and Drug Administration (US FDA) as well as
the  European Food Safety Authority (EFSA). For the past
10  years, this whole cell, astaxanthin-rich material known
commercially as Panaferd® has been used extensively in
the  production of organic salmon and trout intended for
human  consumption.
ccus carotinifaciens indicating the primary ﬂux pathway (solid lines) and
s present in the astaxanthin-rich extract test material.
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With the growing interest in the antioxidant nature of
astaxanthin [15], extracts from algal and yeast sources have
been  prepared and marketed worldwide as a dietary sup-
plement  for human use [16]. Such extracts are generally
provided in an oleoresin format, but microencapsulated
powders containing the extract are also available on the
market.  As an alternative to the algal and yeast sources, we
have  developed a process for the extraction and puriﬁca-
tion  of the carotenoid pigments produced naturally in P.
carotinifaciens. This extract has been shown to exert a pro-
tective  effect (likely to its antioxidant capability) against
induced ulcer formation in a murine gastric ulcer model
[17].  As part of a pre-market safety assessment of this
Astaxanthin-Rich carotenoid Extract (ARE) from P. carotini-
faciens, a 13-week oral toxicity study was conducted in rats.
This  study was conducted in accordance with guidelines
established by the Organization for Economic Co-operation
and Development (OECD) including the Principle of Good
Laboratory Practice (November 26, 1997) and Guidelines
for  the Testing of Chemicals 408 (September 21, 1998)
relating to animal welfare. The study was undertaken under
the  approval of Institutional Animal Care and Use Com-
mittee (IACUC) of the IACUC of testing facility (Gotemba
Laboratory, Japan). The ARE test material used in this
study is a dark red powder which is extracted and puri-
ﬁed  from the whole cells of P. carotinifaciens and is more
than  90% total carotenoids by weight comprising primarily
astaxanthin, but also containing adonirubin, adonixanthin,
canthaxantin, echinenone, 3-hydroxyechinenone, adonix-
anthin  and beta-carotene.
2. Materials and methods
2.1.  Preparation of the astaxanthin-rich extract from P.
carotinifaciens
P.  carotinifaciens biomass was produced by conven-
tional stirred tank aerobic fermentation in a nutrient-rich
liquid medium comprising glucose, ammonia, phosphate,
minerals and vitamins [18]. The pH and concentration of
dissolved  oxygen was controlled to optimize the compo-
sition  of carotenoids and the production of astaxanthin.
At the end of the fermentation period, the mixture was
heat-treated at 80 ± 5 ◦C for 30 ± 10 min  to kill the P. caro-
tinifaciens cells and inactivate endogenous enzymes. The
liquid  mixture of cells and fermentation broth was then
ﬁltered to remove much of the spent medium and washed
with  process water. The concentrated P. carotinifaciens cells
were  then dried and milled. The dried and milled cell pow-
der  was mixed to homogeneity (small, dark-red granules
containing approximately 2% astaxanthin), weighed, and
packaged  in aluminum ﬁlm bags.
The dried P. carotinifaciens whole cell powder was
suspended in hot ethyl alcohol (95–100% in water) in
an  extraction tank to extract the carotenoids. The liq-
uid  mixture was then cooled and ﬁltered to remove the
residual biomass. The ﬁltrate was concentrated and the
carotenoids were allowed to crystallize. The pure crystal-
lized  carotenoid mixture was then collected by ﬁltration
and  dried. The resulting ARE (the test material produced
by  the fermentation and extraction processes describedeports 1 (2014) 582–588
above) used in this study (lot number CK-007) had a black-
purple  crystalline appearance. Chemical analysis of the test
material  indicated that it contained 904.8 mg/g of total
carotenoid and 596.0 mg/g astaxanthin in addition to a
number  of other xanthophylls as shown in Table 1. The
other  components of the ARE included 8% lipid, 1% pro-
tein  and about 1% ash. The phase transition temperature
of the test material as measured by differential scanning
calorimetry (DSC) was  222 ◦C, and the average particle size
(D50) was  59 m.  The shelf life of the ARE at 25 ◦C in an
unopened aluminum ﬁlm bag was 24 months.
2.2. Preparation of formulations containing the test
material
The test formulations used for dosing were pre-
pared by suspending the ARE test material in olive oil
(Japanese Pharmacopoeia, Maruishi Pharmaceutical Co.,
Ltd.).  For each dose concentration, a requisite amount of
the  test material was  weighed, suspended in the olive
oil  and then diluted to a speciﬁed volume. Test sus-
pensions were prepared once a week, transferred to
brown glass bottles, and stored in a refrigerator (4–7 ◦C)
until  used. The test formulations were found to be per-
fectly  stable under these conditions and each formulation
was  tested for concentration and homogeneity at each
dose  level in week 1 and week 13 of the study by
high performance liquid chromatography (HPLC) using
the  following measuring conditions: column: Inertsil
SIL 100A (4.6 mm i.d. × 250 mm,  5 m,  GL Sciences Inc.,
Japan) maintained at room temperature; Mobile phase:
hexane/tetrahydrofuran/methanol (40:20:1); ﬂow rate:
1.0  mL/min; detection: 470 nm;  auto sampler temp: 5 ◦C;
injection  volume: 20 L; measurement time: 18 min. The
measured concentrations of the test suspensions were
within a range of from 96.2 and 106.8% of the expected con-
centrations and with an acceptable coefﬁcient of variation
(CV)  of from 0.4 to 1.5%.
2.3.  Animals and husbandry
Five-week-old  male and female speciﬁc pathogen
free (SPF) Sprague-Dawley (SD) rats were purchased
from Charles River Laboratories (Japan) and quaran-
tined/acclimated for 9 days prior to the start of the
study. The animals were housed in an animal room main-
tained  at 22 ± 3 ◦C, with a relative humidity of 50 ± 20%,
air  ventilation at 12–17 vol/h, and with a 12-h light/dark
cycle. All animals were housed individually in bracket-
type stainless-steel wire mesh cages (W 254 × D 350 × H
170  mm:  Lead Engineering Co., Ltd.) and allowed free
access to a pelleted radiation-sterilized diet (CR-LPF, Ori-
ental  Yeast Co.) and to Gotemba City tap water via an
automatic water supply system.
2.4. Experimental procedureThe  test material dosing volume was 10 mL/kg body
weight for all animals using the ARE dose levels set at 0
(olive  oil), 250, 500 and 1000 mg/kg/day. The test mate-
rial  was  administered on a daily basis by oral gavage using
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Table 1
Carotenoid structures and concentrations (% of dry weight) in the astaxanthin-rich extract test material from Paracoccus carotinifaciens.
Carotenoid wt%  Structure
Astaxanthin 60
Adonirubin 18
Adonixanthin 5
Canthaxanthin 5
Echinenone 2
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l stomach tube for a period of 13-weeks. All animals
ere observed 3 times a day during the administration
eriod (prior to, immediately after, and approximately
–3 h after dosing). On the days of the detailed clinical
bservation the animals were only observed twice a day
prior  to, and immediately after dosing). Detailed clini-
al  observations were conducted once before the start of
dministration, so that any animals that showed abnor-
alities could be excluded from the study, and once
eekly after the daily dosing during the administration
eriod. Detailed clinical observations consisted of a home
age  observation (posture, convulsion, abnormal behav-
or),  an in-the-hand observation (ease of removal from
age,  condition of fur and skin, secretions from eyes and
ose,  exophthalmos, palpebral closure, visible mucous
embrane, autonomic nervous function (lacrimation, sali-
ation,  piloerection, pupil size and abnormal respiration),
eactivity to handling, and vocalization at handling), and
n  open ﬁeld observation (arousal, convulsion, abnor-
al  behavior, stereotypy, gait, posture, grooming, rearing
ount  and excretion (defecation count and urination)). In
he  manipulative test, measurements of grip strength and
otor  activity were conducted in week 12 of the study.
he  manipulative test consisted of auditory responsive-
ess, approach responsiveness, touch responsiveness, pain
esponsiveness, pupillary reﬂex, aerial righting reﬂex, and
anding  foot splay. Grip strength of forelimbs and hindlimbs  was  measured by a digital push pull strain gauge
(MODEL-RX-5; AIKOH Engineering Co., Ltd., Japan). Loco-
motor  activity was  measured for 1 h using an infrared beam
sensor  for experimental animals (NS-AS01 from Neuro-
Science, Inc, Japan), and values in 10-min intervals from
0  to 60 min  were collected. Body weights were recorded
every 3 or 4 days. Food consumption was recorded every 7
days.  Water intake was  measured at the time of urinalysis
conducted in week 13 of the study.
An ophthalmological examination was conducted dur-
ing  the acclimation period (before the start of the
administration period) and in week 13 of the study. Any
animals with abnormalities identiﬁed in the acclimation
period examination that could affect the toxicological eval-
uation  were excluded from the study. All the males and
females in the control group and the high dose group
underwent the ophthalmological examination in week 13
immediately after the routine daily dosing. A mydriatic
agent, Mydrin P (Santen Pharmaceutical Co., Ltd., Japan)
was  initially applied to the eyes for mydriasis and the ante-
rior  part of the eyes, optic media and fundus oculi of all
animals were then examined using an ophthalmoscope
(Omega 200: HEINE Optotechnik GmbH & Co., Germany).Urinalysis was conducted in week 13 of the study. After
dosing on the day of the examination, all animals were indi-
vidually  placed in cages equipped with a urine collector
under deprivation of food but with free access to water,
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and 4-h urine samples were collected. A 20-h urine sam-
ple  was also collected after free access to food and water.
Examination of pH, protein, ketones, glucose, occult blood,
bilirubin  and urobilinogen was done on the ﬁrst 4-h urine
samples  using a urine chemistry autoanalyzer (CLINITEK
500, Siemens Healthcare Diagnostics Inc., USA). Color was
examined  macroscopically, and urinary sediments were
examined microscopically on the ﬁrst 4-h urine samples.
Osmotic pressure was measured on the 20-h urine sam-
ples  using an automatic osmotic pressure meter (OSMO
STATION OM-6060, Arkray Inc., Japan). The electrolytes
(sodium, potassium and chloride) were determined on the
20-h  urine samples using a clinical chemistry autoanalyzer
(TBA-120FR, Toshiba Medical Systems Corporation, Japan).
One  day’s urine volume was calculated by totaling the 4-
h  urine and 20-h urine samples. The daily excretion of
electrolytes was calculated directly from the determined
concentration and urine volume over this 24 h period.
The hematological sampling and assessment was  done
at  necropsy on the day following the end of the adminis-
tration period. All animals were deprived of food overnight
(approximately 16 h) and subjected to abdominal incision
under  isoﬂurane anesthesia. Blood samples were collected
from  the abdominal aorta into blood collection bottles con-
taining  an anticoagulant (EDTA-2K) and analyzed using an
Adiva  120 Hematology System (Siemens Healthcare Diag-
nostics  Inc., USA) for red blood cell count (RBC), hemoglobin
(HGB), hematocrit (HCT), mean corpuscular volume (MCV),
mean  corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), reticulocyte percent-
age  (Retic), platelet count (PLT), white blood cell count
(WBC), and differential white blood cell percentage and
count.  Further, blood samples were collected into tubes
containing 3.8% sodium citrate, and plasma obtained by
centrifugation was examined using a coagulometer (ACL
Elite  Pro, Instrumentation Laboratory, UK) for prothrom-
bin time (PT), activated partial thromboplastin time (APTT)
and  ﬁbrinogen (FIB).
For  blood chemistry, blood samples were collected
from the abdominal aorta into blood collection bottles
containing an anticoagulant (heparin sodium) and ana-
lyzed  using a clinical chemistry autoanalyzer (TBA-120FR,
Toshiba Medical Systems Corporation, Japan) for aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
lactate  dehydrogenase (LDH), alkaline phosphatase (ALP),
total  cholesterol (T-CHO), triglyceride (TG), phospholipids
(PL), total bilirubin (T-BIL), glucose (GLU), blood urea nitro-
gen  (BUN), creatinine (CRNN), sodium (Na), potassium (K),
chloride  (Cl), calcium (Ca), inorganic phosphorus (P), total
protein  (TP), albumin (ALB) and A/G ratio (A/G).
Gross pathology was examined at necropsy and the
organs were weighed (absolute weight) and ﬁxed in 10%
formalin  (vol/vol), and the weight per 100 g body weight
(relative weight) was calculated based on the fasted ani-
mal’s  body weight and absolute organ weight. The gross
pathology of the brain (cerebrum + cerebellum), adrenals,
thymus, spleen, heart, liver, kidneys, testes, epididymides,
ovaries and uterus was  observed and measured. A num-
ber  of organs and tissues were also ﬁxed in 10% formalin
(vol/vol). These included medullary, pons, spinal cord (cer-
vical,  midthoracic and lumbar), sciatic nerves, Harderianeports 1 (2014) 582–588
glands, pituitary, thyroids, parathyroids, submandibular
lymph node, mesenteric lymph node, thoracic aorta,
trachea, lung (including bronchus), tongue, esophagus,
stomach, duodenum, jejunum, ileum (including Peyer’s
patch), cecum, colon, rectum, submandibular glands, sub-
lingual  glands, pancreas, urinary bladder, prostate, seminal
vesicles, vagina, mammary glands (inguinal region), ster-
num  (including bone marrow), femurs (including bone
marrow), femoral skeletal muscles and skin (inguinal
region). The eyeballs and optic nerves were ﬁxed in glu-
taraldehyde/formalin (3%/2% vol/vol in water) and the
testes  and epididymides in Bouin’s solution ﬁrst, and then
preserved in phosphate buffered 10% formalin (vol/vol).
All  preserved organs and tissues in the control and high
dose  groups (1000 mg/kg) were sectioned and stained
with hematoxylin and eosin (H&E) and examined for
histopathology.
2.5.  Statistical analysis
Numerical  data obtained for respective parameters
(quantitative items of open ﬁeld observations, quantitative
items of manipulative tests, measurements of grip strength
and  motor activity, body weight, food consumption, water
intake  and quantitative items of urinalysis as well as data
from  hematology and blood chemistry and organ weight)
were  analyzed using the Bartlett test, Dunnett test, or Steel
test  [19].
3.  Results
No deaths occurred in any of the groups through-
out the administration period. Excretion of dark-red feces
was  observed throughout the administration period in all
males  and females in all treated groups. In the detailed
clinical observations, no treatment-related changes were
observed. In the open ﬁeld observations, a low value in the
rearing  count was recorded in week 3 of administration in
females  in the mid-dose group (500 mg/kg) with statistical
signiﬁcance. However, it was  judged to be incidental since
it  was  not dose-related. In the manipulative tests, measure-
ments of grip strength, and motor activity, no test material
related changes were observed.
There  were no treatment-related changes in body
weight gain in any of the groups and the growth curves of
the  male and female animals during the study were consis-
tent  with historical background data from this test facility
(Fig.  3). The food consumption data (Fig. 4) also tracked
historical norms from this facility, but statistical analysis
revealed that higher food consumption was observed in the
high  dose (1000 mg/kg) male group on day 84 and in the
high  dose (1000 mg/kg) female group on day 77. However,
these changes were judged to be incidental ﬂuctuations
since they were observed at only one time point during the
study.  Likewise a low food consumption recorded on day
14  of administration in females in the 500 mg/kg group was
also  judged to be incidental since it was  a single point and
not  dose-related.
No  treatment-related changes were observed in oph-
thalmology, urinalysis (including water intake), or hema-
tology  in males or females in any treatment group.
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 study of a natural astaxanthin-rich carotenoid extract in rats.
no treatment-related changes were observed in organ
weights. Although a statistically signiﬁcant higher value
in  the absolute weight of the brain was  recorded in males
in  the low dose group (250 mg/kg) and a low value in the
relative spleen weight in males in the mid  dose group
(500 mg/kg), they were considered to be incidental changes
only  in the absolute or relative weight and were not related
to  the dose of the test material.
4.  Discussion
In this study, the only treatment-related changes
observed were the excretion of dark-red feces in all males
and  females in all treated groups throughout the adminis-
tration period. However, this was  due to excretion of the
colored  test material into feces and was  not suggestive of
toxicity.  Based on these results, the 13-week repeated dose
oral  administration of a natural astaxanthin-rich extract
49 56 63 70 77 84 91
ay)
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xicity study of a natural astaxanthin-rich carotenoid extract in rats.
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Table  2
Hematology parameters at the conclusion of a 13-week repeated oral dose toxicity study of a natural astaxanthin-rich carotenoid extract in rats.
Sex Dose (mg/kg) No. of rats examined Eos ratio (%) PT (s) APTT (s) FIB (mg/dL)
Male 0 10 1.1 ± 0.3 12.0 ± 0.8 17.2 ± 2.2 271 ± 22
250  10 1.1 ± 0.4 13.4 ± 0.9** 18.5 ± 1.9 269 ± 27
500  10 1.5 ± 0.3* 14.1 ± 2.2** 19.5 ± 1.8 262 ± 26
1000  10 1.3 ± 0.5 13.7 ± 1.9 19.8  ± 2.5* 272 ± 21
Female  0 10 1.3 ± 0.4 11.1 ± 0.6 14.2 ± 1.4 177 ± 14
250  10 1.4 ± 0.3 10.9 ± 0.6 13.7 ± 1.5 160 ± 14*
500 10 1.6 ± 0.5 10.8 ± 0.4 14.5 ± 1.5 170 ± 15
1.6 ± 0
[
[
[
[
[
[
[
[
[
[
[
chronic  toxicity studies in rats, Food Chem. Toxicol. 46 (9) (2008)1000  10 
* p ≤ 0.05 (signiﬁcantly different from the control group mean).
** p ≤ 0.01 (signiﬁcantly different from the control group mean).
(ARE) from P. carotinifaciens to rats at dose levels of 250,
500  and 1000 mg/kg/day was not associated with any sig-
niﬁcant  toxic changes. Therefore, it was concluded that the
no  observed adverse effect level (NOAEL) in this study was
at  least 1000 mg/kg/day for both males and females.
These  data are consistent with previous observations
and conclusions for the whole P. carotinifaciens cell material
now  used extensively in the organic aquaculture indus-
try  [14]. They are also consistent with studies on other
astaxanthin-containing microbes such as H. pluvialis [20]
and  P. rhodozyma [21] when the whole biomass itself has
been  tested. Although the oleoresin extracts from algal and
yeast  sources are presently on the market, we are unaware
of  any previously published subchronic toxicological eval-
uation  in rats similar to the present study that has been
completed for those sources of astaxanthin. Nevertheless,
the present study does demonstrate that with the puri-
ﬁed  astaxanthin-rich extract from P. carotinifaciens, there
appear  to be no signiﬁcant observable adverse effects in
rats  when consumed at dose levels considerably higher
than  levels being used presently by the supplements indus-
try  (5–15 mg/person/day).
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